Opthea to have presence at 24th EURETINA Congress

Opthea announced scientific presentations and a non-CME educational lunch symposium highlighting sozinibercept’s potential to become the first therapy in 20 years to improve visual outcomes in wet AMD patients at the European Society of Retina Specialists Annual Conference — EURETINA Innovation Spotlight, September 18, 2024, and the 24th EURETINA Congress, September 19-22, 2024, being held at the CCIB in Barcelona, Spain. “We are excited to connect with retina experts from around the world at EURETINA,” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. “Presentations by retina thought leaders featuring sozinibercept’s mechanism of action, the design of our ongoing Phase 3 trials, as well as further insights into our previously presented data on superior visual gains in wet AMD patients provide an opportunity to highlight sozinibercept’s potential to deliver superior efficacy beyond current standard-of-care anti-VEGF-A treatments.” With the completion of patient enrollment in Opthea’s Phase 3 pivotal program evaluating the superiority of sozinibercept combination therapy in wet AMD, the Company is planning to announce topline data for COAST in early Q2 CY2025 and for ShORe in mid-year CY 2025.